- Home
- ATGL vs OBIO Comparison
ATGL vs OBIO Comparison
Compare ATGL & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATGL | OBIO |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.7M | 237.2M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | ATGL | OBIO |
|---|---|---|
| Price | $23.50 | $4.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 64.2K | ★ 299.6K |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,206,460.00 | ★ $2,818,000.00 |
| Revenue This Year | N/A | $36.43 |
| Revenue Next Year | N/A | $2.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 2.36 | ★ 6.46 |
| 52 Week Low | $9.01 | $2.20 |
| 52 Week High | $57.32 | $6.30 |
Technical Indicators
Market Signals| Indicator | ATGL | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 53.00 | 52.07 |
| Support Level | $24.01 | $4.19 |
| Resistance Level | $26.20 | $4.69 |
| Average True Range (ATR) | 2.79 | 0.31 |
| MACD | 0.10 | -0.08 |
| Stochastic Oscillator | 43.16 | 27.15 |
Price Performance
Historical ComparisonAbout ATGL Alpha Technology Group Limited
Alpha Technology Group Ltd operates through its subsidiaries, which are established cloud-based IT solution service providers in Hong Kong. Its Operating Subsidiaries utilize its analytic skills, programming skills, artificial intelligence technologies and technological know-how to provide comprehensive solutions designed to optimize the business performance of customers, meet various industry-specific operational challenges of customers and create new business opportunities for customers. The Operating Subsidiaries provide services for customers from a variety of industries, including consulting, real estate, architectural design, carpark management, electronic payment services, logistics, investments, retail, textiles, wholesale and distribution, etc.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.